

#412
425.02
RECEIVED

APR 10 2002

TECH CENTER 1600/2900

ARC 2863N1

Response to First Office Action

1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail
under 37 CFR §1.8 in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this
date: March 11, 2002 By: Maria E. Valenzuela

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): GUPTA, et al.

Serial No.: 09/801,443

Filed: 3/07/01

For: OXYBUTYNIN THERAPY

Group Art Unit: 1615

Examiner: TRAN, S.

**Amendment in Response to
First Office Action**

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

AMENDMENT

Sir/Madam:

This correspondence is in response to the Office Action mailed September 11, 2001, regarding the above-entitled application for which the time to respond is respectfully extended through March 11, 2002 with acceptance of Applicants' petition for a three month extension of time. Reconsideration of this application is requested.

Please amend the application as follows.

IN THE CLAIMS

a 1. (Amended) A sustained release dosage form comprising oxybutynin for use in managing the plasma concentration of oxybutynin and dry mouth associated with the use of oxybutynin, wherein the sustained dosage form upon once daily administration is characterized by the sustained release of a